Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Am J Ophthalmol. 2011 Aug 16;152(6):1014–1020. doi: 10.1016/j.ajo.2011.05.008

Table 4.

Mean number of services for neovascular age-related macular degeneration provided per year in matched sample

1994 cohort
(N= 2,488)
Mean (Min,
Max,
Median)		 2000 cohort
(N=2,488)
Mean (Min,
Max,
Median)		 p-value 2006 cohort
(N= 2,488)
Mean (Min,
Max,
Median)		 p-value
Visits 2.1 (0,21,2) 2.0* (0,15,2) 0.0302 3.5** (0,27,3) <0.0001
Fluorescein angiography 1.6 (0,16,1) 1.7**(0,22,1) 0.0002 1.6 (0,21,1) 0.4008
Optical coherence tomography 0 (0,0,0) 0.03**(0,2,0) <0.0001 2.1** (0,17,1) <0.0001
Anti-vascular endothelial growth factor (VEGF) injections 0 (0,0,0) 0 (0,0,0) N/A 2.0 (0,19,0) N/A (anti-VEGF injections not available in 1994 and 2000)